HANSOH PHARMA(HK:03692) Jin Rong Jie·2025-08-20 02:04Group 1 - The core viewpoint of the news is that Hansoh Pharmaceutical (03692) is experiencing a significant drop in stock price due to a planned share placement at a discount, which aims to raise funds for various R&D initiatives [1][2] Group 2 - Hansoh Pharmaceutical's stock fell over 7% in early trading, currently down 6.03% at HKD 36.48, with a trading volume of HKD 270 million [1] - The company plans to place 108 million shares at HKD 36.3 each, representing a discount of approximately 6.49% from the previous closing price of HKD 38.82 [1] - The net proceeds from the placement are expected to be around HKD 38.97 billion, with approximately 65% allocated for R&D of new innovative drugs in oncology, autoimmune, central nervous system, and metabolic diseases [1] - About 25% of the funds will be used to build new innovative drug production facilities and R&D laboratories, as well as upgrade existing facilities [1] - The remaining 10% will be allocated for working capital and other general corporate purposes [1] Group 3 - The company reported a mid-year revenue of HKD 74.34 billion, a year-on-year increase of 14.3%, and a net profit attributable to shareholders of HKD 31.35 billion, up 15.0% year-on-year [2] - The performance exceeded expectations, primarily due to milestone payments from the collaboration with GSK [2] - Revenue from innovative drugs and collaborative products reached HKD 61.45 billion, a 22.1% increase year-on-year, accounting for 82.7% of total revenue, up 5.3 percentage points year-on-year [2] - Collaborative revenue was HKD 16.56 billion, mainly from the upfront payment for the oral GLP-1 licensed to Merck and milestone payments from GSK [2] - In June 2025, the company licensed overseas rights for the GLP-1/GIP receptor agonist HS-20094 to Regeneron, receiving an upfront payment of USD 80 million and milestone payments of USD 1.93 billion, which will enhance performance in the second half of 2025 [2]